Related Experiment Video

Updated: Oct 14, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.3K

[Antiangiogenic therapy for types I and II macular neovascularization in age-related macular degeneration]

M V Budzinskaya1, A V Shelankova1, A A Andreeva1

  • 1Research Institute of Eye Diseases, Moscow, Russia.

Vestnik Oftalmologii
|November 2, 2021
PubMed

Insights

Anti-VEGF therapy effectively stabilizes visual acuity in patients with both types of neovascular age-related macular degeneration (AMD). This treatment promotes the resorption of subretinal fluid, showing significant functional and morphological benefits.

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Vascular Biology

Background:

  • Neovascular age-related macular degeneration (AMD) involves abnormal blood vessel growth.
  • Macular neovascularization (MNV) is classified as type 1 (sub-RPE) or type 2 (intraretinal).
  • Fluid accumulation and RPE detachment are key features of neovascular AMD.

Purpose of the Study:

  • To retrospectively analyze anti-VEGF therapy outcomes in AMD patients with type I and type II MNV.
  • To evaluate the efficacy of anti-VEGF treatment for different MNV classifications.

Main Methods:

  • Retrospective analysis of 89 AMD patients with active MNV over 3 years.
  • Standard ophthalmological examinations including visometry, biomicroscopy, ophthalmoscopy, and optical coherence tomography.
  • Assessment of best corrected visual acuity (BCVA), intraretinal fluid (IRF), and subretinal fluid (SRF).

Main Results:

  • Anti-VEGF therapy stabilized BCVA in both type I and type II MNV.
  • Subretinal fluid (SRF) resorption was more pronounced than intraretinal fluid (IRF) resolution.
  • By year three, 60% of patients showed RPE detachment, while 40% had persistent IRF.

Conclusions:

  • Antiangiogenic therapy demonstrates significant functional and morphological effectiveness for both type I and type II MNV.
  • Anti-VEGF treatment is a valuable therapeutic option for managing neovascular AMD.
Keywords:
age-related macular degenerationchoroidal neovascularizationintraretinal fluidretinal pigment epithelium detachmentsubretinal fluid

More Related Videos

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K
Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy09:46

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

3.3K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
748
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
887